Use of olaparib in patients with advanced gastric cancer - Authors' reply

Affiliations

Comment

Yung-Jue Bang. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):e76.

doi: 10.1016/S1470-2045(18)30030-5.

¹ Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea. Electronic address: bangyj@snu.ac.kr.

No abstract available

Comment on

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Bang YJ, et al. Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2. Lancet Oncol. 2017. PMID: 29103871 Clinical Trial.
Use of olaparib in patients with advanced gastric cancer.
Mo M, Yang J, Zhu X, Zhu J. Mo M, et al. Lancet Oncol. 2018 Feb;19(2):e75. doi: 10.1016/S1470-2045(18)30023-8. Lancet Oncol. 2018. PMID: 29413476 No abstract available.